MoCA Cognition
MoCA Cognition (MoCA Test Inc.) develops and licenses the Montreal Cognitive Assessment (MoCA), a 30-question cognitive screening tool with 90% sensitivity for mild cognitive impairment, serving healthcare professionals, researchers, pharmaceutical companies, and consumers globally via paper, mobile, and self-assessment formats.
- Company typePrivate
- Founded2005
- HeadquartersGreenfield Park, Canada
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What MoCA Cognition does
MoCA Cognition (legally MoCA Test Inc.) is a privately held Canadian health technology company headquartered in Greenfield Park, Quebec, that develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a brief 30-question cognitive screening tool validated for early detection of mild cognitive impairment (MCI). The company was founded by neurologist Dr. Ziad Nasreddine, who developed MoCA during his clinical work, validated the test in 2000, and officially published it in 2005. MoCA Cognition serves healthcare professionals (nurses, primary care and specialty physicians, occupational therapists, speech-language pathologists, psychologists, and researchers), pharmaceutical companies, and consumer end-users, operating alongside an affiliated MoCA Memory Clinic in the Montreal area that serves more than 2,000 patients annually.
The company's product portfolio includes the paper-based MoCA (PDF downloads), the Digital MoCA delivered via the MoCA Duo tablet application on iOS and Android (which provides automated administration and scoring, machine-learning-enhanced accuracy, and EHR integration), the MoCA Training and Certification Program (mandatory for paper-based use since September 2019 with biennial recertification), specialized variants (MoCA Basic for low-education populations, MoCA Blind for visually impaired patients, alternate versions 8.2 and 8.3 to mitigate memorization effects), and the consumer-facing MoCA-XpressO self-assessment platform launched in March 2024. The MoCA test is available in more than 100 languages and dialects, has been validated in more than 7,000 peer-reviewed studies cited across 26,000+ articles, and was named the most widely used MCI detection tool by the 2021 World Alzheimer Report and ranked #1 among 53 cognitive screening tests by a 2023 global Delphi consensus.
MoCA Cognition operates a hybrid revenue model: the MoCA app and paper-based test are free for individual healthcare professionals and academia, while paid streams include professional organizational subscriptions (approximately USD 10 per month per evaluator), training and certification packages for organizations, and multi-year commercial and pharmaceutical licensing agreements. Distribution combines direct website downloads, major app stores, and partner-led international rollout — most notably a March 2026 launch of a Japanese version of MoCA-XpressO via Teoria Technologies Co., Ltd. (Eisai Group), targeting Japan's estimated 5 million people with MCI. Data practices comply with GDPR (Article 9) and Canadian PIPEDA. The company is founder-controlled with no disclosed institutional investors, parent company, or subsidiaries.
MoCA Cognition firmographics
Firmographics- Name
- MoCA Cognition
- Legal name
- MoCA Test Inc.
- Website
- https://mocacognition.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MoCA Cognition (MoCA Test Inc.) develops and licenses the Montreal Cognitive Assessment (MoCA), a 30-question cognitive screening tool with 90% sensitivity for mild cognitive impairment, serving healthcare professionals, researchers, pharmaceutical companies, and consumers globally via paper, mobile, and self-assessment formats.
- Ownership category
- akta.pro rank
MoCA Cognition industry classification
Industry- Product category
- Cognitive Assessment Software
- NAICS
- Medical and Diagnostic Laboratories (6215), Software Publishers (5132)
- SIC
- Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Home-Use & OTC Rapid Self-Tests (Consumer POCT kits) (HLAHAOAK)
- akta.pro secondary industry
- Diagnostic & Adaptive Assessment Content (Skills/Readiness) (EDAGADAJ)
Keywords
Where MoCA Cognition is headquartered
LocationHeadquarters
- HQ city
- Greenfield Park
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
MoCA Cognition business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Professional App Subscription: MoCA Duo mobile application is free for healthcare professionals and academia, with a professional subscription paid tier for organizations requiring enhanced features or multi-user management.
- Training and Certification Program: Training and certification for administering and scoring the MoCA test is available for purchase by organizations. Free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.
- Commercial Licensing: Written permission and licensing agreements are required for commercial entities and pharmaceutical companies wishing to use, reproduce, or distribute the MoCA test. Clinical use by universities, foundations, hospitals, and public health institutes is free without permission but requires licensing if funded by a commercial entity or pharma.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | — | Free tier for individual healthcare professionals and academia |
| Freemium | — | Training and Certification — Free for eligible users |
| Subscription | Annual | Training and Certification — Organizational purchase |
| Per seat | Monthly | MoCA App — Professional subscription |
| Subscription | Multi-year contract | Commercial/Pharma Licensing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
MoCA Cognition product offering
Product offeringCore offering
MoCA Cognition develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a copyrighted, validated 30-question cognitive screening tool for early detection of mild cognitive impairment (MCI) — available in paper PDF format and as the MoCA Duo tablet app with automated scoring and EHR integration. The company also sells a mandatory Training and Certification program for clinicians (free for students, faculty, and publicly operated healthcare institution employees) and operates the consumer-facing MoCA-XpressO digital self-assessment platform launched in March 2024.
Product overview
MoCA Cognition offers a portfolio of cognitive assessment products centered on the MoCA (Montreal Cognitive Assessment) test — a brief 30-question screening tool for mild cognitive impairment (MCI) with 90% sensitivity. The core offerings comprise the paper-based MoCA (PDF downloads) and the Digital MoCA via the MoCA Duo tablet app. The digital app includes automated administration and scoring and integrates with EHR systems. Supporting products include the MoCA Training and Certification Program (mandatory for paper-based use, recommended for digital), and specialized variants such as MoCA Basic (for low-education populations) and MoCA Blind (for visually impaired users). Alternate versions (8.2, 8.3) are available for repeated administrations. A new consumer-facing self-assessment tool, MoCA-XpressO, was launched in March 2024 for the general public. The company is headquartered in Greenfield Park, Quebec, Canada, and is led by Dr. Ziad Nasreddine.
Differentiator
Problem solved
Functional benefit
Brands
- MoCA-XpressO: Digital self-assessment platform for cognitive health launched March 2024, enables users to assess risk of cognitive decline in 5 minutes
- MoCA Duo
Products and services
- Digital MoCA (MoCA Duo App) Tablet-based digital MoCA assessment tool for healthcare organizations and researchers with mobile tablet capability; delivers automated scoring, sub-scores, and time-to-completion metrics, and can upload results to EHR systems. Free for healthcare professionals and academia, with a paid professional subscription at ~USD 10/evaluator/month for organizations needing multi-user management.
- MoCA-XpressO Digital self-assessment platform for cognitive health targeting the general public, enabling risk assessment of cognitive decline in approximately 5 minutes based on the internationally recognized MoCA theory. Accessible via mocaxpresso.com / portal.mocacognition.com without needing a healthcare professional.
- MoCA Training and Certification Program Official standardized training and certification program for administering and scoring the MoCA test, including sub-score interpretation. Mandatory for paper-based clinical, research, and educational use and recommended for Digital MoCA; free for full-time students, faculty, academic researchers, and employees of publicly operated healthcare institutions upon providing proof of eligibility.
- MoCA Commercial Licensing Formal written licensing and permission grants allowing commercial entities and pharmaceutical companies to use, reproduce, or distribute the MoCA test (and digital derivatives) within clinical research, drug development, or commercial programs. Universities, foundations, hospitals, and public health institutes can use MoCA clinically/academically without permission but require licensing if funded by a commercial entity or pharma source.
Quantifiable outcome
- 90% sensitivity for detecting mild cognitive impairment (vs. 18% for MMSE)
- +3 more outcomes
Companies that use MoCA Cognition
Customer profileNamed customers2 records
Ideal customer profiles4 records
MoCA Cognition technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
MoCA Cognition partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, flagship and minor.
- Teoria Technologies Co., Ltd. (Eisai Group)coreTeoria Technologies Co., Ltd., a member of the Eisai Group, launched a Japanese version of MoCA-XpressO, a digital self-check tool for cognitive function based on the MoCA theory. This partnership addresses Japan's growing need for early dementia detection amid an estimated 5 million people with Mild Cognitive Impairment. The company plans to expand adoption through partnerships with local governments and integration into corporate health check programs.
- ADI (Alzheimer's Disease International)flagshipADI (Alzheimer's Disease International) published a case study highlighting MoCA Cognition's MoCA-XpressO digital self-assessment platform for cognitive health. The case study demonstrates how digital self-assessment tools can normalize conversations about cognitive health and encourage earlier medical consultation, validating MoCA-XpressO's role in population-level cognitive health screening.
- UCLA (University of California, Los Angeles)coreDr. Ziad Nasreddine completed a fellowship in cognitive neurology and neurobehavior at UCLA. UCLA collaborators Jeffrey Saver and Mario Mendez are acknowledged contributors to MoCA's development and validation. UCLA-based research has contributed to the validation of MoCA across multiple clinical conditions.
- McGill University (Serge Gauthier)coreSerge Gauthier from McGill University is listed as a key collaborator in MoCA's development, contributing to the validation and clinical adoption of the cognitive assessment tool in academic and clinical settings.
- Cleveland Clinic (Jeffrey Cummings)coreJeffrey Cummings from the Cleveland Clinic is listed as a collaborator in MoCA's development. Cummings is a renowned expert in Alzheimer's disease and dementia research, lending clinical and research credibility to the MoCA assessment tool.
- Baycrest Health Sciences (Howard Chertkow)coreHoward Chertkow from Baycrest is a collaborator on the MoCA project. Baycrest is a leading academic health sciences center focused on aging and brain health, contributing to the clinical validation and research behind MoCA.
- CHUM (Centre hospitalier de l'Université de Montréal)minorRaymonde Labrecque and Simon Charbonneau from CHUM are listed as collaborators. Their contributions support the French-language validation and clinical research applications of MoCA in Quebec and francophone populations.
- Concordia University (Natalie Phillips)minorNatalie Phillips from Concordia University is a recognized contributor to MoCA's research and validation, supporting cognitive assessment research and normative data development.
- UQAM (Université du Québec à Montréal)minorIsabelle Rouleau from UQAM is listed as a collaborator, supporting MoCA's academic research and development in Quebec's university ecosystem.
- Jewish General Hospital / Mémoire — Hôpital générale juifminorVictor Whitehead from the Jewish General Hospital and the Mémoire clinic are collaborators, contributing to clinical validation and patient care applications of MoCA in hospital settings.
- Western University (Vladimir Hachinski)minorVladimir Hachinski from Western University is a collaborator, contributing expertise in vascular cognitive impairment and stroke-related cognitive assessment to MoCA's clinical development.
Scale indicators7 records
Recent moves5 records
Expansion highlights5 records
MoCA Cognition competitors and assessment
Company assessmentEmerging players
- Neurotrack: Digital cognitive assessment and lifestyle program for early detection of cognitive decline, targeting a similar consumer/professional audience as MoCA-XpressO.
- Winterlight Labs: Speech-based digital biomarker platform for cognitive impairment assessment, intersecting with MoCA's mission of early MCI detection through a different modality (voice vs. questionnaire).
- Posit Science (BrainHQ): Cognitive training and assessment company with clinically validated brain training exercises, partially overlapping with MoCA's cognitive health screening audience.
Direct peers
- Altoida: FDA-cleared digital cognitive assessment platform using AR/AI on smartphones, competing with MoCA's digital app for early detection of MCI and Alzheimer's.
- Linus Health: Digital cognitive assessment platform using tablet-based tests and AI to detect cognitive impairment, directly competing with MoCA Duo and XpressO in primary care and consumer brain health.
- Cogstate: Offers computerized cognitive testing across clinical trials, healthcare, and research with comparable sensitivity/standardization claims to MoCA, serving overlapping pharma and academic customers.
- BrainCheck: Digital cognitive assessment and care management platform for clinicians, providing a tablet-based alternative to MoCA in primary care and neurology workflows.
- Cambridge Cognition: Provides computerized cognitive testing (CANTAB) for clinical trials and healthcare, directly competing with MoCA in digital cognitive assessment for research and clinical settings.
- Creyos (Cambridge Brain Sciences): Online cognitive assessment platform for healthcare providers and researchers, offering computerized tests comparable in target use case to MoCA's professional offering.
Others
- Cerveau Technologies: Provides tau PET imaging biomarkers for Alzheimer's disease research and clinical trials; complementary to MoCA as a screening-plus-imaging diagnostic pathway for the same patient population.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
MoCA Cognition social profiles
Digital presenceMoCA Cognition compliance and trust
Trust signalCompliance2 records
MoCA Cognition financial estimates
Financial estimateRevenue estimate
Valuation estimate
MoCA Cognition leadership team
Management profileNumber of profiles
Profiles1 record
MoCA Cognition funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MoCA Cognition M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MoCA Cognition
What does MoCA Cognition do?
MoCA Cognition develops, distributes, and licenses the Montreal Cognitive Assessment (MoCA) — a copyrighted, validated 30-question cognitive screening tool for early detection of mild cognitive impairment (MCI) — available in paper PDF format and as the MoCA Duo tablet app with automated scoring and EHR integration. The company also sells a mandatory Training and Certification program for clinicians (free for students, faculty, and publicly operated healthcare institution employees) and operates the consumer-facing MoCA-XpressO digital self-assessment platform launched in March 2024.
Is MoCA Cognition a public or private company?
MoCA Cognition is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MoCA Cognition founded?
MoCA Cognition was founded in 2005. It employs 51 to 100 people.
Where is MoCA Cognition based?
MoCA Cognition is headquartered in Greenfield Park, Canada, in the North America region.
How does MoCA Cognition make money?
Three revenue lines are on record. Professional App Subscription is the primary driver. The others are training and Certification Program and commercial Licensing.
Who are MoCA Cognition's main competitors?
Emerging players on record are Neurotrack, Winterlight Labs and Posit Science (BrainHQ). Direct peers are Altoida, Linus Health, Cogstate, BrainCheck, Cambridge Cognition and Creyos (Cambridge Brain Sciences). Cerveau Technologies is listed as an others.
Does MoCA Cognition have an API?
No public API is recorded for MoCA Cognition.
What industry is MoCA Cognition in?
MoCA Cognition's product category is Cognitive Assessment Software. Its primary akta.pro industry code is HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits), with a secondary code of EDAGADAJ, Diagnostic & Adaptive Assessment Content (Skills/Readiness). Its NAICS code is 6215 and its SIC code is 8071.